© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution
Experimental Physiology and Pharmacology Section, Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
* Corresponding author. Cardiology Branch, NHLBI, NIH, Building 10, Room 7B15, 10 Center Drive MSC 1650, Bethesda, MD 20892-1650, Tel.: +1-301-496-0021; Fax: +1-301-402-0888; e-mail: lazaroud@gwgate.nhlbi.nih.gov
Objective: We have shown that basic fibroblast growth factor (bFGF/FGF-2) enhances myocardial collateral development in a canine model of progressive coronary occlusion when delivered via the left atrial or intracoronary routes; however, we have found intravenous bFGF ineffective in the same model. Data on the fate and efficacy of intravenous bFGF are limited. We hypothesized that first pass lung uptake might limit myocardial bFGF availability after intravenous injection. We postulated that delivery of bFGF through the distal port of a wedged Swan Ganz catheter might circumvent this problem by restricting exposure of bFGF to a limited number of pulmonary binding sites. This study evaluated differential regional uptake of 125I labeled bFGF following bolus intravenous, Swan Ganz, left atrial, intracoronary, and pericardial delivery. Methods: Mongrel dogs were used. Human recombinant bFGF, monoiodinated with 125I, was mixed with cold bFGF to a specific activity of 0.03 µCi/µg. Approximately 100 µg/kg was injected per animal by the intravenous, left atrial, Swan Ganz, intracoronary, or pericardial route. Dogs were killed 15 min or 150 min later. The heart, lungs, liver, spleen, and kidneys were harvested and 125I activity was assessed. Immunohistochemical and pharmacokinetic studies were also performed. Results: Serum half life of bFGF was comparable after intracoronary, intravenous and left atrial delivery (50 min); however, there were significant differences with regard to pharmacodynamics. After intracoronary administration, 3–5% of the total bFGF dose was recovered from the heart, with the peptide immunolocalized to the extracellular matrix and vascular endothelium. In contrast, only 1.3% of the injected bFGF was localized to the heart after left atrial administration, and 0.5% was recovered after intravenous or Swan Ganz delivery. Pericardial administration resulted in substantial cardiac bFGF delivery; 19% was present at 150 min. Myocardial uptake was similar with Swan Ganz and intravenous delivery, suggesting that the administered dose did not saturate available pulmonary binding sites. Conclusions: These data predict efficacy of intracoronary, left atrial, and pericardial bFGF for myocardial angiogenesis, and a lack of efficacy after bolus intravenous and Swan Ganz administration.
KEYWORDS Angiogenesis; bFGF; Pharmacodynamics; Myocardium; Growth factors; Dog
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. N. Le, C.-W. Hwang, A. R. Tzafriri, M. A. Lovich, A. Hayward, and E. R. Edelman Vascular Regeneration by Local Growth Factor Release Is Self-Limited by Microvascular Clearance Circulation, June 9, 2009; 119(22): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Seko, N. Nitta, A. Sonoda, S. Ohta, M. Takahashi, K. Murata, and Y. Tabata Vascular Regeneration by Repeated Infusions of Basic Fibroblast Growth Factor in a Rabbit Model of Hind-Limb Ischemia Am. J. Roentgenol., June 1, 2009; 192(6): W306 - W310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]
|
|
|
|
 |
|
 S. Grundmann, N. van Royen, G. Pasterkamp, N. Gonzalez, E. J. Tijsma, J. J. Piek, and I. E. Hoefer A New Intra-Arterial DeliveryPlatform for Pro-Arteriogenic Compounds to Stimulate Collateral Artery Growth Via Transforming Growth Factor-{beta}1 Release J. Am. Coll. Cardiol., July 24, 2007; 50(4): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lee, H. J. Chung, and T. G. Park Perspectives On: Local and Sustained Delivery of Angiogenic Growth Factors Journal of Bioactive and Compatible Polymers, January 1, 2007; 22(1): 89 - 114. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Geer, D. D. Swartz, and S. T. Andreadis Biomimetic Delivery of Keratinocyte Growth Factor upon Cellular Demand for Accelerated Wound Healing in Vitro and in Vivo Am. J. Pathol., December 1, 2005; 167(6): 1575 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Filion and A. S. Popel Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H263 - H279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hosaka, H. Koyama, T. Kushibiki, Y. Tabata, N. Nishiyama, T. Miyata, H. Shigematsu, T. Takato, and H. Nagawa Gelatin Hydrogel Microspheres Enable Pinpoint Delivery of Basic Fibroblast Growth Factor for the Development of Functional Collateral Vessels Circulation, November 23, 2004; 110(21): 3322 - 3328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.L Grines The AGENT clinical trials programme Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E18 - E23. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. C. Hughes, S. S. Biswas, B. Yin, R. E. Coleman, T. R. DeGrado, C. K Landolfo, J. E. Lowe, B. H. Annex, and K. P. Landolfo Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF Ann. Thorac. Surg., March 1, 2004; 77(3): 812 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Biswas, G. C. Hughes, J. E. Scarborough, P. W. Domkowski, L. Diodato, M. L. Smith, C. Landolfo, J. E. Lowe, B. H. Annex, and K. P. Landolfo Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: A comparative study J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 34 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. von Degenfeld, P. Raake, C. Kupatt, C. Lebherz, R. Hinkel, F. J. Gildehaus, W. Munzing, A. Kranz, J. Waltenberger, M. Simoes, et al. Selective Pressure-Regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1120 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sakakibara, K. Tambara, G. Sakaguchi, F. Lu, M. Yamamoto, K. Nishimura, Y. Tabata, and M. Komeda Toward surgical angiogenesis using slow-released basic fibroblast growth factor Eur. J. Cardiothorac. Surg., July 1, 2003; 24(1): 105 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-E. Luyt, A. Meddahi-Pelle, B. Ho-Tin-Noe, S. Colliec-Jouault, J. Guezennec, L. Louedec, H. Prats, M.-P. Jacob, M. Osborne-Pellegrin, D. Letourneur, et al. Low-Molecular-Weight Fucoidan Promotes Therapeutic Revascularization in a Rat Model of Critical Hindlimb Ischemia J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 24 - 30. [Abstract] [Full Text]
|
|
|
|
|
|
J. J. R. Hermans, H. van Essen, H. A. J. Struijker-Boudier, R. M. Johnson, F. Theeuwes, and J. F. M. Smits Pharmacokinetic Advantage of Intrapericardially Applied Substances in the Rat J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Lindner and T. Maciag The Putative Convergent and Divergent Natures of Angiogenesis and Arteriogenesis Circ. Res., October 26, 2001; 89(9): 747 - 749. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Post, R. Laham, F. W. Sellke, and M. Simons Therapeutic angiogenesis in cardiology using protein formulations Cardiovasc Res, February 16, 2001; 49(3): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res, February 16, 2001; 49(3): 532 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sato, R. J. Laham, J. D. Pearlman, D. Novicki, F. W. Sellke, M. Simons, and M. J. Post Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia Ann. Thorac. Surg., December 1, 2000; 70(6): 2113 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Mallery, P. Pei, J. Kang, G. Zhu, G. M. Ness, and S. P. Schwendeman Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts Carcinogenesis, September 1, 2000; 21(9): 1647 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Operschall, L. Falivene, J.-P. Clozel, and S. Roux A new model of chronic cardiac ischemia in rabbits J Appl Physiol, April 1, 2000; 88(4): 1438 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kornowski, M. B. Leon, S. Fuchs, Y. Vodovotz, M. A. Flynn, D. A. Gordon, A. Pierre, I. Kovesdi, J. A. Keiser, and S. E. Epstein Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy: Results in normal and ischemic porcine models J. Am. Coll. Cardiol., March 15, 2000; 35(4): 1031 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. S. Rajanayagam, M. Shou, V. Thirumurti, D. F. Lazarous, A. A. Quyyumi, L. Goncalves, J. Stiber, S. E. Epstein, and E. F. Unger Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs J. Am. Coll. Cardiol., February 1, 2000; 35(2): 519 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kornowski, S. Fuchs, M. B. Leon, and S. E. Epstein Delivery Strategies to Achieve Therapeutic Myocardial Angiogenesis Circulation, February 1, 2000; 101(4): 454 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.C. Hughes, B. H. Annex, B. Yin, A. M. Pippen, P. Lin, A. P. Kypson, K. G. Peters, J. E. Lowe, and K. P. Landolfo Transmyocardial laser revascularization limits in vivo adenoviral-mediated gene transfer in porcine myocardium Cardiovasc Res, October 1, 1999; 44(1): 81 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Laham, M. Rezaee, M. Post, F. W. Sellke, R. A. Braeckman, D. Hung, and M. Simons Intracoronary and Intravenous Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution Drug Metab. Dispos., July 1, 1999; 27(7): 821 - 826. [Abstract] [Full Text]
|
|
|
|
|
|
J. R Kersten, P. S Pagel, W. M Chilian, and D. C Warltier Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia Cardiovasc Res, July 1, 1999; 43(1): 44 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Waxman, R. Moreno, K. A. Rowe, and R. L. Verrier Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery J. Am. Coll. Cardiol., June 1, 1999; 33(7): 2073 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hasegawa, A. Kimura, M. Miyataka, M. Inagaki, and K. Ishikawa Basic Fibroblast Growth Factor Increases Regional Myocardial Blood Flow and Salvages Myocardium in the Infarct Border Zone in a Rabbit Model of Acute Myocardial Infarction Angiology, June 1, 1999; 50(6): 487 - 495. [Abstract] [PDF]
|
|
|
|
|
|
R. L. Verrier, S. Waxman, E. G. Lovett, and R. Moreno Transatrial Access to the Normal Pericardial Space : A Novel Approach for Diagnostic Sampling, Pericardiocentesis, and Therapeutic Interventions Circulation, November 24, 1998; 98(21): 2331 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Favaloro Landmarks in the Development of Coronary Artery Bypass Surgery Circulation, August 4, 1998; 98(5): 466 - 478. [Full Text] [PDF]
|
|